Cost-Effectiveness of Sirolimus-Eluting Stents for Treatment of Complex Coronary Stenoses: The SIRIUS Trial - PowerPoint PPT Presentation

Slide1 l.jpg
1 / 17

  • Uploaded on
  • Presentation posted in: General

Cost-Effectiveness of Sirolimus-Eluting Stents for Treatment of Complex Coronary Stenoses: The SIRIUS Trial.

I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.

Download Presentation

Cost-Effectiveness of Sirolimus-Eluting Stents for Treatment of Complex Coronary Stenoses: The SIRIUS Trial

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript

Slide1 l.jpg

Cost-Effectiveness of Sirolimus-Eluting Stents for Treatment of Complex Coronary Stenoses: The SIRIUS Trial

David J. Cohen, MD, MSc Ameet Bakhai, MD, Chunxue Shi, MS, Louise Githiora, Ronna H. Berezin, MPH, Ronald P. Caputo, M.D., Charles O’Shaugnessy, M.D., Martin B. Leon, MD, Jeff Moses, MD,, Richard E. Kuntz, MD, MSc, on behalf of the SIRIUS Investigators

Harvard Clinical Research InstituteBoston, MA

Conflicts of interest l.jpg

Conflicts of Interest

Study funding

  • Cordis, Inc.

    Other Research Grants

  • Millenium Pharmaceuticals

  • The Medicines Company

  • Eli Lilly

  • Guidant

  • Boston Scientific

  • Medtronic

Background l.jpg


  • Recent studies have demonstrated that sirolimus-eluting stents dramatically reduce both angiographic and clinical restenosis compared with conventional stenting

  • The incremental cost of this technology is substantial, however, and may pose a barrier to widespread adoption at both the hospital and health system level

  • Nonetheless, sirolimus-eluting stents may be reasonably cost-effective if follow-up costs are substantially reduced due to avoidance of rehospitalization and repeat revascularization procedures

Objectives l.jpg


  • To compare the in-hospital and long-term costs of PCI using the sirolimus-eluting stent with those of PCI using conventional, bare metal stents

  • To examine the overall cost-effectiveness of the sirolimus-eluting stent compared with conventional stenting in patients undergoing PCI of “real world” coronary lesions

  • To examine the impact of clinical restenosis on long-term costs of care for patients undergoing PCI in contemporary practice

Patient population l.jpg


Patient Population

Inclusion Criteria

  • De novo coronary lesion documented myocardial ischemia

  • Lesion length 15-30 mm (visual estimate)

  • Reference vessel diameter 2.5 – 3.5 mm (visual estimate)

Patient population6 l.jpg


Patient Population

Exclusion Criteria

  • Planned multivessel or staged PCI

  • Major sidebranch involvement

  • Total occlusion

  • Ostial location

  • Recent MI

  • Chronic renal insufficiency

  • Allergy to ASA or thienopyridine

Slide7 l.jpg

Randomized Patients (n=1101)

Deregistered (n=23)

Deregistered (n=20)

Sirolimus-Eluting BX Velocity Stent (n=533)

Control BX Velocity Stent (n=525)

9 month primary endpoint: Target Vessel Failure

12-month clinical f/u


Sirius study administration l.jpg

SIRIUS - Study Administration

Principal investigators: M.B. Leon and J.W. Moses, Lenox Hill Hospital & CRF, New York NY

Study coordination: R.E. Kuntz, Harvard Clinical Research Institute and Brigham and Women’s Hospital, Boston MA

Angiographic core lab: J.J. Popma, Brigham and Women’s Hospital, Boston MA

IVUS core lab: P. Fitzgerald, Stanford Medical Center, Palo Alto, CA

Economic core lab: R. Berezin, T. Lavelle, L. Githiora, C. Shi, A. Bakhai, HCRI and BIDMC, Boston MA

Sponsor: Cordis, A Johnson & Johnson Company, Warren, N.J.

Baseline characteristics clinical l.jpg


Baseline Characteristics: Clinical

P= NS for all comparisons

Angiographic characteristics l.jpg


Angiographic Characteristics

P= NS for all comparisons

Procedural resource utilization and cost l.jpg


Procedural Resource Utilization and Cost

Initial hospital costs l.jpg


Initial Hospital Costs

D = $2880 (p<0.001)

$11,345 ± 3211 *

$8464 ± 2497

* P<0.001 vs. Control


12 month events repeat revascularization l.jpg


12-Month Events: Repeat Revascularization




12 month events type of revascularization l.jpg


12-Month Events: Type of Revascularization



Slide15 l.jpg


1-Year Medical Care Costs

D = +$309 (p=0.64)

$16,813 + 9737

$16,504 + 11,511

Sirius cost effectiveness results l.jpg

SIRIUS: Cost-Effectiveness Results

Summary conclusions l.jpg


  • These results suggest that use of the sirolimus-eluting stent is highly cost-effective for the target population of the SIRIUS trial

  • Availability of longer stents and improved implantation techniques should further enhance the cost-effectiveness of this technology in the immediate future.

  • Further studies are necessary to extend these findings to other populations including diffuse disease, SVG disease, and multivessel PCI

  • Login